Blood TRPC6 mRNA as a biomarker for Alzheimer's disease: a nationwide, multicenter study in China
Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · 2026-10 · 18 (4)
DOI: 10.1002/dad2.70433 ↗Abstract
Abstract INTRODUCTION Accessible blood‐based biomarkers remain needed for Alzheimer's disease (AD) screening and diagnosis. We investigated whether blood transient receptor potential canonical 6 (TRPC6) could serve as a potential biomarker for AD. METHODS We enrolled 1254 individuals, including 366 patients with AD, 735 cognitively unimpaired (CU) individuals, and 153 individuals with non‐AD neurological disorders. All patients with AD were confirmed to be amyloid beta positive (Aβ+) by Aβ positron emission tomography (PET). Blood TRPC6 messenger RNA (mRNA) levels were measured in all participants. In a subset, Aβ PET imaging and plasma biomarker assessments were performed. RESULTS Blood TRPC6 mRNA levels differed significantly among the CU, AD, and non‐AD groups, with the lowest levels observed in patients with AD. TRPC6 mRNA levels were associated with regional Aβ deposition and showed diagnostic performance comparable to several established plasma biomarkers, although slightly inferior to phosphorylated tau 217. DISCUSSION Blood TRPC6 mRNA is markedly reduced in AD and may represent an accessible and clinically relevant blood biomarker for AD.
EUVIMED